ARCHIVES

IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

Includes May Business & Regulatory Report (8-page issue).

June 6, 2003

FDA Approves Iressa For Third-Line Treatment Of Non-Small Cell Lung Cancer

May 9, 2003

NCI, Private Groups, Promote Mammograms To Blacks, Hispanics

April 25, 1992

White House Seek Elimination Of NCI’s Bypass Budget Authority In Legislation Renewing Cancer Act

April 9, 1982

USPSTF’s Michael LeFevre: Lung Screening Can Save More Lives With Fewer Screens Than Mammography

August 2, 2013

Senate Committee Adds $100 Million for Cancer, Earmarks Extra Positions for NCI, Backs New Construction

September 19, 1975